Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical Overview

A review arguing that much of the wide patient-to-patient variability in immunosuppressant handling, and therefore much rejection and toxicity, traces back to genetic differences in drug-metabolising enzymes and transporters. It makes the case for validated sequencing-based pharmacogenetic panels to guide dosing in kidney transplant recipients.